Pelthos Therapeutics (PTHS) Non Operating Interest Expenses (2024 - 2026)

Pelthos Therapeutics has reported Non Operating Interest Expenses for 3 years, with the latest figure at $4.7 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 2075.23% year-over-year to $4.7 million in Q2 2026; TTM through Jun 2026 was $9.8 million, a 1854.91% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 283.21% from the prior year.
• Non Operating Interest Expenses was $4.7 million for Q2 2026 at Pelthos Therapeutics, up from $2.4 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $4.7 million in Q2 2026, with the low at $39000.0 in Q3 2024.
• Average Non Operating Interest Expenses over 3 years is $1.3 million, with a median of $766000.0 recorded in 2025.
• The largest YoY upside for Non Operating Interest Expenses was 3351.28% in 2025 against a maximum downside of 1116.67% in 2025.
• Over 3 years, Non Operating Interest Expenses stood at $108000.0 in 2024, then soared by 1116.67% to $1.3 million in 2025, then jumped by 260.88% to $4.7 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $4.7 million (Q2 2026), $2.4 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.